Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes

OBJECTIVE: Quick-release bromocriptine (bromocriptine-QR), a D2 dopamine receptor agonist, is indicated as a treatment for type 2 diabetes. The Cycloset Safety Trial, a 52-week, randomized, double-blind, multicenter trial, evaluated the overall safety and cardiovascular safety of this novel therapy...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gaziano, J. Michael, Cincotta, Anthony H., O'Connor, Christopher M., Ezrokhi, Michael, Rutty, Dean, Ma, Z.J., Scranton, Richard E.
Format: Artigo
Jezik:Inglês
Izdano: American Diabetes Association 2010
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2890350/
https://ncbi.nlm.nih.gov/pubmed/20332352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc09-2009
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki